Ashraf Mallak – Managing Director GCC, MSD
MSD GCC’s Ashraf Mallak looks back on a “transformational” two years since his last PharmaBoardroom interview back in 2021, with the set up of a new regional office, a raft…
Merck & Co., Inc., d.b.a. Merck Sharp & Dohme (MSD) outside the United States and Canada, is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668. Merck & Co. was established as an American affiliate in 1891.
The company is ranked 69th on the 2021 Fortune 500 and 92nd on the 2021 Forbes Global 2000, both based on 2020 revenues.
The company develops medicines, vaccines, biologic therapies and animal health products. In 2020, the company had 6 blockbuster drugs or products, each with over $1 billion in revenue: Keytruda (pembrolizumab), a humanized antibody used in cancer immunotherapy that had $14.3 billion in 2020 revenue; Januvia (sitagliptin), an anti-diabetic medication used to treat type 2 diabetes that had $5.3 billion in 2020 revenue; Gardasil, an HPV vaccine that had $3.9 billion in 2020 revenue; Varivax, a varicella vaccine used to protect against chickenpox that had $1.9 billion in 2020 revenues; Bridion (Sugammadex), a neuromuscular-blocking drug that had $1.2 billion in 2020 revenue; and Pneumovax 23, a pneumococcal polysaccharide vaccine that had $1.1 billion in 2020 revenue. Other major products by the company include Isentress (raltegravir), an antiretroviral medication used to treat HIV/AIDS that had $857 million in 2020 revenue; Simponi (golimumab), a human monoclonal antibody used as an immunosuppressive drug that had $838 million in 2020 revenue; RotaTeq, a rotavirus vaccine that had $797 million in 2020 revenue; and Lynparza (olaparib), a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults that generated $725 million in 2020 revenue for the company.
Contact:
Address: 2000 Galloping Hill Road, Kenilworth, NJ 07033 U.S.A.
Tel: 908-740-4000
MSD GCC’s Ashraf Mallak looks back on a “transformational” two years since his last PharmaBoardroom interview back in 2021, with the set up of a new regional office, a raft…
MSD’s managing director for Hong Kong and Macau, Vincent Tong, came to lead the affiliate during the COVID-19 pandemic. He outlines the challenges and opportunities of a challenging time, discusses…
Managing Director of MSD Greece, Cyprus & Malta Agata Jakoncic, who also serves as president of Greece’s PhRMA Innovation Forum (PIF), draws on her three decades of industry experience to…
Sarah Aiosa oversees the entire Latin America region for MSD, where the global giant is looking to build on its 100-year legacy by better addressing the continent’s health inequities and…
MSD’s managing director for Egypt, Libya, Sudan and Yemen, Hazem Abdel Samie, shares his perspective on recent changes within the American multinational and explains why Egypt’s move from a predominantly…
Nicoletta Luppi, MSD Italia’s Senior Vice President & Managing Director details the need for healthcare reform in Italy and walks us through MSD’s portfolio priorities. In addition, she explains the…
After almost two decades with MSD, Ashraf Mallak, managing director for the company in the GCC region, dives into the often-overlooked healthcare capabilities of the Gulf countries, including the fact…
After being present in the Turkish market for more than 28 years, MSD seems confident that it will be able to seize upcoming opportunities due to the country’s high prevalence…
MSD’s Catherine Williams, a recent arrival in Copenhagen, gives her first impressions of the Danish healthcare system and pharma market, drawing on experiences in her native UK to compare the…
Switzerland is a crucial country for MSD’s global network, employing over 1000 people in local, regional, and global functions across four sites in Lucerne and a newly opened site in…
MSD’s Ashish Pal describes how he led the Singapore, Malaysia, and Brunei cluster through a challenging 2020; the importance of leveraging learnings from the past year to create a more…
Alain Barry, managing director of MSD in Morocco, shares how the organization is partnering with the Moroccan healthcare community to ensure that patients have access to innovative therapies and vaccines.…
Brecht Vanneste, associate VP and managing director of MSD in Belgium and Luxembourg, highlights the strategic significance of the affiliate as an important location for early-stage clinical trials and home…
Speaking at the 2020 European Cancer Forum in Brussels, MSD’s Deepak Khanna outlines the progress that the company is making at the forefront of oncological innovation, the importance of multi-stakeholder…
Merck (MSD outside of the USA) is celebrating its 70-year anniversary in Puerto Rico this year. Executive Managing Director Wendy Perry highlights the company’s extensive footprint on the island which…
Kevin Peters, Managing Director of MSD in Thailand, highlights the strategic significance and strong performance of the affiliate as a top three pharmaceutical player in Thailand. Kevin goes on to…
Jakob Tellgren recently returned from MSD’s US headquarters to his home country of Sweden to take the helm of the Nordic and Baltic countries. He shares the importance of Sweden…
Renan Ozyerli of MSD Turkey provides insights into the transformation of Turkey’s healthcare ecosystem over the past decade, highlighting how MSD works hand-in-hand with the government to broaden access to…
Angel Fernandez, president and managing director of MSD Spain and Portugal, covers the company´s current pipeline and portfolio strategy. He also explains how the company collaborate with a wide variety…
Jacqueline Anastassiades has been involved in the development of the Cypriot healthcare sector for more than 10 years as the Managing Director of MSD. With the upcoming healthcare reforms,…
Having just announced a major investment into a new UK Discovery Centre in London that is set to open in 2020, MSD is committed to leverage on the UK’s potential…
A strong supporter of public-private partnerships, MSD’s managing director in India, Vivek Kamath, explains how the company’s collaborative approach is the key to enhancing their reputation, improving patient outcomes and…
Nebojsa Skuljec has held various positions in MSD Healthcare across the Balkans before his promotion to country lead for Serbia and Balkans emerging markets 14 months ago. In this interview…
Denis Vujičić, managing director of MSD Poland, discusses his overriding mission to give Polish patients greater access to breakthrough therapies and highlights the affiliate’s extensive R&D capabilities that entail both…
Urszula Orzel, general manager at MSD Bulgaria, explains how the affiliate has become one of the fastest growing players in the country and emphasizes that pharmaceutical companies are not merely…
Guillermo Browne, General Manager at MSD Colombia, reveals the strategic importance of the Colombian affiliate, hosting a global data management centre and regional pharmacovigilance operations, while highlighting the company’s commitment…
Ashish D. Pal, President Director at MSD Indonesia, discusses the importance of introducing innovative pharmaceuticals, vaccines and biologics to address significant unmet needs and the strategic importance of the universal…
Ger Brennan, MD (Human Health) of MSD Ireland, highlights his mandate to position MSD for success in an evolving healthcare landscape, the groundbreaking new report on Irish healthcare attitudes and…
Beaver Tamesis, Managing Director at MSD Philippines, discusses the company’s impressive growth in recent years as well as their expanding portfolio. Additionally, he discusses his work to foster engagement and…
The CEO of MSD Italy discusses the company’s promising pipeline, its plans to realize growth through the launch of innovative new drugs in 2016, the paths towards a sustainable healthcare…
The Managing Director of MSD Egypt highlights MSD’s unique incentives to further collaborate with the Egyptian medical community and explains how market peculiarities shape product launches in developing countries like…
The managing director of MSD in Mexico explains why the Mexican pharmaceutical market is an attractive market in which to compete, but not one that will deliver 12 to 15…
MSD Turkey has benefited in recent years from the ability to engage in local business development initiatives, and managing director Hatice Demiray has prioritized initiatives such as reducing internal bureaucracy…
One of the so-called ‘new generation’ of pharmaceutical GMs in Romania outlines his first impressions of the local market and details how MSD has managed to shape in-county developments in…
Guillermo Browne, Managing Director of MSD Peru, talks about the turnover of the affiliate and the company’s success in bringing new innovation to the country, particularly in the areas of vaccines…
The managing director of MSD for Morocco, Tunisia, and French West Africa explains why the company has chosen Morocco as its hub for the region, discusses the difficulties associated with…
The executive managing director of a leading American healthcare provider offering an innovative range of products on the local Algerian market treating asthma, diabetes, hepatitis and cholesterol speaks about the…
Don Hyun, president of MSD Korea, shares his vision to bring Korean pharmaceutical companies to the global stage and to bring a locally produced drug to blockbuster status in the…
Ricardo Brage serves as Vice President Spain for Sanofi Pasteur MSD. He discusses how he sought to change the subsidiary in response to pricing reforms as well as the challenges…
“We have implemented a strategic plan with a key objective to put Chile on the map. We are seeing major market opportunities in the country”, says Carlos Cicogna, Managing Director,…
Why did MSD decide to have Denmark as the headquarters for the Mid Europe 2 region? This Mid Europe 2 region consists of 10 countries, most of them clustered around the…
You have significant experience in a number of therapeutic areas such as immunology, CNS, or biotech. What competitive edge would you say this gives you over other general managers in…
In 2008, MSD began building a human vaccine facility in Carlow—a 220MN EUR investment that the company expanded upon last year with an additional 7Mn EUR. What is the importance…
In 2010, you gave a lecture for the Great Place to Work Institute, and spoke about how you have navigated the change and rapid growth MSD Ireland has experienced in…
In Q3 2012, MSD reported worldwide sales of $11.5 billion. What was the contribution that emerging markets had? From an MSD perspective, emerging markets refer to every market outside North…
It truly seems that you have pharma in your genes, with a father who successfully developed a migraine drug in addition to your 4 years practicing medicine and now continuing…
Dr. Novotný, in 2008, you became Managing Director for MSD for the Czech and Slovak Republics. In the very next year after your appointment, you were tasked with managing the…
If we take a look at MSD’s international presence, the group has grown into the third largest pharma company in the world. Here in South Africa, you are in the…
You have only just arrived from Korea to head the Romanian operations at MSD. Just recently, you told in an interview with Medica Academica that MSD Romania enjoys a good…
Stefan Oschmann, President of the Emerging Markets at Merck and Co. described MSD as the dark horse of the emerging markets. How is MSD performing in Malaysia? Since the merger…
We read in an article by El Economista last year that you believe “there is no other company with such a diverse range of therapies as MSD and that makes…
What have been the key milestones and accomplishments in the company development since you took the helm almost four years ago? First of all, and for me personally, moving from…
MSD China’s Michel Vounastos gives his initial impressions of the opportunities and challenges inherent in the Chinese healthcare market, and highlights how MSD’s offerings are able to address specific gaps…
When we were in Australia, we met with the “star scientist” Ian Frazier, who was Australian of the Year in 2009 for his co-discovery of Merck’s Gardasil. Or Singulair, which…
While your appointment as Managing Director was not a long time ago, you immediately faced the big task to oversee one of the most complicated corporate mergers the local Indian…
You have been in Russia now for a bit less than a year, having come from the former Schering-Plough’s Hungary office to run the Russian MSD affiliate. In our conversation…
You were previously managing the Merck/Schering-Plough joint venture in the US, and arrived in the UK 2 years ago. What did you set out for yourself as head of the…
Karyopharm Therapeutics’ Dr Michael G. Kauffman outlines the genesis of the company he co-founded with his wife, the approval journey of key product XPOVIO®, his ambitious internationalisation plans, and the…
Ivan Cheung, head of Japanese firm Eisai’s US operations, highlights the significance of a potential 2021 US FDA approval for Alzheimer’s Disease drug aducanumab, developed in collaboration with Biogen. Cheung…
Holmusk’s Nawal Roy outlines why a cure for Alzheimer’s Disease is the “Holy Grail” of medicine today, the reasons for so many biotech companies failing to develop effective treatments for…
PharmaBoardroom recently spoke to CNS-focused Danish biopharma company Lundbeck’s EVP and Head of North America Peter Anastasiou, who highlighted the long-term damage COVID-19 is causing to the general mental health…
Sanofi has agreed a deal to buy out its partner, US biotech company Principia Biopharma for USD 3.7 billion in cash, giving the French giant full ownership of Principia’s pipeline…
Industry veteran Peter Anastasiou, executive VP and head of North America for Danish CNS specialist Lundbeck, outlines the performance of Lundbeck’s specialty portfolio in the US market, the challenges of…
Executives from ALK, Sanofi Genzyme and Novartis discuss how they are navigating pricing and reimbursement issues in the USA, home to the world’s largest – but perhaps most complex –…
With COVID-19 having wreaked havoc on global operations, the pharma industry is understandably focused on leveraging its collective resources and knowhow in discovering and delivering prophylactics and therapeutics against the…
Ameet Mallik, Executive VP and Head of Oncology for the US at Novartis Oncology highlights the company’s culture of ‘curious, inspired, and unbossed,’ how Novartis differentiates itself in a highly…
Alper Ureten, Amgen VP and General Manager, sits down with PharmaBoardroom to set out his ambitions and objectives for its Biosimilars Business Unit. Ureten also reveals the strategy behind their…
William H Lewis, chairman and CEO of serious and rare disease specialist Insmed, talks through the impact of recent product approvals in the US, preparations underway for international launches, the…
Ulrich Neumann examines the debate around drug pricing in the US and why it is not going away any time soon. Come senators, congressmen Please heed the call Don’t…
See our Cookie Privacy Policy Here
